December 23, 2010
In boceprevir studies, including the present one, for the first four weeks of therapy participants received peginterferon + ribavirin. The purpose of this lead-in phase of peginterferon is to assess participants' ability to respond to peginterferon and assess any changes in HCV viral load. Among participants in the present study whose HCV viral loads fell by at least one log after the first four weeks of therapy (in other words, who had a significant response to peginterferon), SVRs were as follows:
One death occurred during the Respond 2 study in a person who received boceprevir.
Most side effects were evenly distributed across all three groups, except for these which were more common among boceprevir users:
Anemia occurred as follows:
Altered sense of taste occurred in the following proportion of participants:
The use of boceprevir significantly increased the changes of SVR even in participants who had not previously responded to peginterferon therapy. Both strategies of boceprevir use (response-guided and taking it for 44 weeks) seemed equally effective in people whose previous treatment with peginterferon + ribavirin had failed.
As in other studies, boceprevir was associated with an increased risk of anemia and altered sense of taste in the present study.
No comments have been made.